-25% en todo – hasta el 31 de octubreEnvío gratis en pedidos desde $99
SwissChems

Uso del producto: Este producto está destinado exclusivamente a la investigación.

Toda la información de los productos de este sitio web tiene fines exclusivamente educativos. Cualquier forma de introducción en el cuerpo de personas o animales está estrictamente prohibida por la ley. Este producto solo debe ser manipulado por profesionales autorizados y cualificados. No es un medicamento, alimento ni cosmético y no debe etiquetarse, utilizarse ni presentarse como tal.

Ipamorelin 2mg

La misma fórmula de confianza. Nuevo diseño.

Durante el cambio de envase, puedes recibir productos con la etiqueta anterior o con la nueva. La formulación, la pureza y la calidad siguen siendo exactamente las mismas, según nuestros estándares.

Métodos de pago aceptados
  • Tarjeta de crédito
  • Transferencia bancaria (SEPA inmediata)
  • Transferencia bancaria (ACH)
  • Wise
  • Revolut
  • Zelle
  • Remitly
  • Western Union
  • Chime
  • Otros

-25% en todo – hasta el 31 de octubre
25% sobre los precios habituales, en sustitución de otras ofertas. Acumulable solo con el descuento crypto.

Envío

Envío en el día para pedidos en EE. UU. realizados antes de las 12:00 EST.

Ver la política de envíos →
Devoluciones

Devoluciones sin complicaciones en 30 días para productos sin abrir.

Ver la política de devoluciones →
Analizado en laboratorio

Cada lote se analiza para comprobar su pureza, potencia y calidad.

Ver resultados de laboratorio →
Atención al cliente

¿Tienes alguna pregunta? Escríbenos por Telegram.

Abrir el chat →

Ipamorelin is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). The compound is characterized by strong receptor selectivity and a well-defined pharmacological profile, making it a useful tool for investigating GHS-R1a-mediated signal transduction and ligand-receptor interactions.

Research applications include GHS-R1a pharmacology, receptor activation kinetics, signaling pathway characterization, structure-activity relationship investigations, and comparative analyses of growth hormone secretagogue receptor ligands.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

3D Molecular Structure

Drag to rotate · scroll to zoom
Loading 3D structure…
Ipamorelin-2mg1 vial | KIT (10 vials)
Chemical Formula C38H49N9O5
Synonyms 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide, 170851-70-4, C38H49N9O5, CHEMBL58547, SCHEMBL183305, SCHEMBL8169698, MolPort-039-139-953, 5020AF, ZINC29562299, AKOS030573449, DB12370, NCGC00167295-01, FT-0696037
Molar Mass 711.9 g/mol
CAS Number 170851-70-4
PubChem CID 9831659
Total Compound Content 2 mg per vial
Shelf Life 36 months
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). Its defining pharmacological characteristic is a high degree of receptor selectivity relative to earlier growth hormone secretagogue receptor ligands, making it a valuable tool for investigating GHS-R1a-mediated signaling pathways and ligand-receptor interactions. Activation of GHS-R1a by Ipamorelin initiates Gq/11-coupled phospholipase C signaling, resulting in IP3 and DAG second-messenger generation, intracellular calcium mobilization, and downstream signal transduction events. Pharmacokinetic investigations have characterized the compound's receptor engagement profile and elimination dynamics in experimental systems. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signal transduction characterization, structure-activity relationship investigations, and comparative analyses of selective growth hormone secretagogue receptor ligands. Supplied as a lyophilized preparation (2 mg/vial). Independently third-party HPLC-tested; COA available per batch.

Results refer to the tested sample. Check the batch and date in the report.

Ipamorelin (2605-ED-IP)
September 13, 2026
Ipamorelin (2607-ED-IP)
September 13, 2026
Ipamorelin (2608-CY-IP)
September 13, 2026
Ipamorelin (AY0811-IP2)
September 4, 2026
Ipamorelin (2606CYIP)
August 26, 2026
Ipamorelin (ED9630)
June 16, 2026
What makes Ipamorelin more selective than other GHS-R1a agonists?

Ipamorelin is characterized by a highly selective interaction with GHS-R1a and a well-defined pharmacological profile relative to earlier growth hormone secretagogue receptor ligands. This selectivity makes it a valuable research tool for investigating GHS-R1a-mediated signaling pathways, receptor activation kinetics, and ligand-receptor interactions without the broader receptor activity observed with less selective secretagogues.

What is the pharmacokinetic profile of Ipamorelin?

Pharmacokinetic investigations have reported a relatively short elimination profile compared with longer-acting GHS-R1a agonists. This characteristic makes Ipamorelin useful for studies examining receptor engagement dynamics, activation kinetics, signal transduction timing, and the temporal aspects of GHS-R1a-mediated signaling.

How does Ipamorelin compare with GHRH analogues in receptor pharmacology research?

Ipamorelin and GHRH analogues interact with distinct receptor systems and signaling pathways. Ipamorelin acts through GHS-R1a, whereas compounds such as CJC-1295 and Sermorelin target the growth hormone-releasing hormone receptor (GHRHR). Comparative investigations utilize these compounds to examine differences in receptor activation mechanisms, downstream signaling architecture, ligand selectivity, and pathway-specific signal transduction.